Cargando…

Predictors of fulvestrant long-term benefit in hormone receptor-positive/HER2 negative advanced breast cancer

We retrospectively investigated in women treated with fulvestrant for HR+/HER2 negative advanced breast cancer clinical, pathological and molecular features associated with long-term benefit from treatment defined as being progression-free at 18 months. Specifically, we analyzed on formalin-fixed pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Torrisi, Rosalba, Vaira, Valentina, Giordano, Laura, Destro, Annarita, Basilico, Vera, Mazzara, Saveria, Salvini, Piermario, Gaudioso, Gabriella, Fernandes, Bethania, Rudini, Noemi, Masci, Giovanna, Santoro, Armando
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329443/ https://www.ncbi.nlm.nih.gov/pubmed/35896637 http://dx.doi.org/10.1038/s41598-022-16409-7

Ejemplares similares

Clinical predictors of cardiac toxicity in HER2-positive early breast cancer patients treated with adjuvant s.c. versus i.v. trastuzumab
por: De Sanctis, Rita, et al.
Publicado: (2021)

Insights for the application of TILs and AR in the treatment of TNBC in routine clinical practice
por: Losurdo, Agnese, et al.
Publicado: (2020)

Never too old to fight breast cancer: A case report
por: Zuradelli, Monica, et al.
Publicado: (2018)

Sticking to the Rules: Outcome and Success Rate of Guideline-Based Diarrhea Management in Metastatic Breast Cancer Patients Treated with Abemaciclib
por: Jacobs, Flavia, et al.
Publicado: (2023)

HR(+)/HER2(−) de novo metastatic breast cancer: a true peculiar entity?
por: Torrisi, Rosalba, et al.
Publicado: (2023)

Retrospective Evaluation of Fulvestrant Efficacy and Clinical Results in Patients Using Fulvestrant
por: Kut, Engin, et al.
Publicado: (2023)

Comparative efficacy & safety of buparlisib plus fulvestrant, fulvestrant plus dalpiciclib, and ribociclib plus letrozole for postmenopausal, hormone receptor-positive, and HER2-negative breast cancer
por: Liu, Qi, et al.
Publicado: (2023)

Phase II trial of fulvestrant plus enzalutamide in ER+/HER2− advanced breast cancer
por: Elias, Anthony D., et al.
Publicado: (2023)

Fulvestrant: pharmacokinetics and pharmacology
por: Robertson, J F R, et al.
Publicado: (2004)

Clinical benefit of fulvestrant monotherapy in the multimodal treatment of hormone receptor and HER2 positive advanced breast cancer: a case series
por: Rusz, Orsolya, et al.
Publicado: (2018)

Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives
por: Iorfida, Monica, et al.
Publicado: (2020)

Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy
por: Colombo, Giorgio Lorenzo, et al.
Publicado: (2023)

ER+, HER2− advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes
por: Chen, Jessica W., et al.
Publicado: (2023)

Fulvestrant-induced toxic epidermal necrolysis
por: Morales-Conde, Macarena, et al.
Publicado: (2019)

A Review of Fulvestrant in Breast Cancer
por: Nathan, Mark R., et al.
Publicado: (2017)

Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial
por: Schmid, Peter, et al.
Publicado: (2019)

Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial
por: Tibau, Ariadna, et al.
Publicado: (2023)

Revisiting Fulvestrant Dosing in Uncertain Economic Times
por: Patel, Amol, et al.
Publicado: (2021)

Abemaciclib plus fulvestrant in East Asian women with HR+, HER2− advanced breast cancer: Overall survival from MONARCH 2
por: Toi, Masakazu, et al.
Publicado: (2022)

Mutation profile and immunoscore signature in thymic carcinomas: An exploratory study and review of the literature
por: Asselta, Rosanna, et al.
Publicado: (2021)

Plasmablastic lymphoma: one or more tumors?
por: Pileri, Stefano A., et al.
Publicado: (2021)

Fulvestrant and the sequential endocrine cascade for advanced breast cancer
por: Johnston, S
Publicado: (2004)

Oestradiol measurement during fulvestrant treatment for breast cancer
por: Owen, Laura J., et al.
Publicado: (2019)

Abemaciclib/fulvestrant: Leucopenia and Covid-19: case report
Publicado: (2020)

Fulvestrant-Big Mac Index: Defining Inequality in Oncology
por: O'Reilly, David, et al.
Publicado: (2021)

Combined treatment with everolimus and fulvestrant reversed anti-HER2 resistance in a patient with refractory advanced breast cancer: a case report
por: Sun, Bing, et al.
Publicado: (2016)

Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor
por: García-Sáenz, José Á., et al.
Publicado: (2022)

TOSCA: an automated Tumor Only Somatic CAlling workflow for somatic mutation detection without matched normal samples
por: Del Corvo, Marcello, et al.
Publicado: (2022)

Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2− Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series †
por: Orlandi, Armando, et al.
Publicado: (2020)

Effectiveness of Alpelisib + Fulvestrant Compared with Real‐World Standard Treatment Among Patients with HR+, HER2–, PIK3CA‐Mutated Breast Cancer
por: Turner, Stuart, et al.
Publicado: (2021)

Pulmonary sarcomatoid carcinoma presenting both ALK rearrangement and PD-L1 high positivity: A case report on the therapeutic regimen
por: D’Antonio, Federica, et al.
Publicado: (2019)

Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action
por: Osborne, C K, et al.
Publicado: (2004)

Fulvestrant in advanced breast cancer: evidence to date and place in therapy
por: Boér, Katalin
Publicado: (2017)

Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer
por: Orlando, Laura, et al.
Publicado: (2006)

Clinical Review on the Management of Breast Cancer Visceral Crisis
por: Benvenuti, Chiara, et al.
Publicado: (2023)

Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2− Advanced Breast Cancer
por: Fasching, Peter A, et al.
Publicado: (2021)

Alpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with PIK3CA-Mutated HR+/HER2– Advanced Breast Cancer
por: Jacobson, Anne
Publicado: (2022)

Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2–, PIK3CA-mutated breast cancers
por: Hutchinson, Katherine E., et al.
Publicado: (2023)

Cost-effectiveness of palbociclib plus fulvestrant as second-line therapy of women with HR+/HER2- advanced breast cancer - A Chinese healthcare system perspective
por: Zhu, Wentao, et al.
Publicado: (2023)

Fulvestrant treatment of precocious puberty in girls with McCune-Albright syndrome
por: Sims, Emily K, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_lfiidkl97sst0ugp4tsm47pte3